NicotinevsPanax Ginseng

Nicotine binds to nicotinic acetylcholine receptors (nAChRs), particularly the high-affinity alpha-4-beta-2 subtype predominant in the brain, causing conformational changes that open the cation channel and allow Na+ and Ca2+ influx, depolarizing the neuron. This triggers vesicular release of dopamine (VTA to nucleus accumbens and prefrontal cortex), norepinephrine (locus coeruleus), acetylcholine (basal forebrain), serotonin, and glutamate. Cognitive enhancement comes from increased acetylcholine in the prefrontal cortex and hippocampus (attention, working memory) and dopamine in mesocortical pathways (motivation, executive function). Nicotine upregulates BDNF through nAChR-mediated Ca2+ signaling and CREB activation, and has anti-inflammatory effects via microglial alpha-7 nAChRs. Neuroprotection may involve reduced excitotoxicity and enhanced neuronal survival pathways.

Ginsenosides (Rb1, Rg1, Rg3, Re, and others) have diverse pharmacological actions. They modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol release under stress through glucocorticoid receptor modulation. Ginsenosides inhibit acetylcholinesterase (AChE), increasing acetylcholine levels in the hippocampus and enhancing muscarinic and nicotinic receptor function. They enhance nitric oxide production via endothelial nitric oxide synthase (eNOS) for cerebral vasodilation. Rb1 and Rg1 promote BDNF and NGF expression through activation of CREB and TrkB/TrkA signaling, supporting neuroplasticity. Rg1 specifically enhances hippocampal neurogenesis via the PI3K/Akt pathway and Wnt/β-catenin signaling, and improves spatial learning in animal models. Ginsenosides may also modulate GABA-A receptors and have antioxidant properties.